A phase Ib/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (study 111/KEYNOTE-146): Long-term efficacy and safety update Journal Article
| Authors: | Makker, V.; Aghajanian, C.; Cohn, A. L.; Romeo, M.; Bratos, R.; Brose, M. S.; Messing, M.; Dutta, L.; Dutcus, C. E.; Huang, J.; Schmidt, E. V.; Orlowski, R.; Taylor, M. H. |
| Article Title: | A phase Ib/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (study 111/KEYNOTE-146): Long-term efficacy and safety update |
| Abstract: | Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The open-label phase Ib/II Study 111/KEYNOTE-146 of daily lenvatinib 20 mg plus pembrolizumab 200 mg once every 3 weeks showed promising efficacy and tolerable safety in patients with previously treated advanced endometrial carcinoma (EC; primary data cutoff date: January 10, 2019). This updated analysis reports long-term follow-up efficacy and safety data from 108 patients with previously treated EC included in the primary analysis. End points included objective response rate, duration of response, progression-free survival, overall survival, and safety. Investigators performed tumor assessments per immune-related RECIST. At the updated data cutoff date (August 18, 2020), the median study follow-up duration was 34.7 months (95% CI, 30.9 to 41.2), the objective response rate was 39.8% (95% CI, 30.5 to 49.7), and the median duration of response was 22.9 months (95% CI, 10.2 to not estimable). The median progression-free survival and overall survival were 7.4 months (95% CI, 5.2 to 8.7) and 17.7 months (95% CI, 15.5 to 25.8), respectively. Treatment-related treatment-emergent adverse events of any grade occurred in 104 (96.3%) patients. The most common grade ≥ 3 treatment-related treatment-emergent adverse events were hypertension (33.3%), elevated lipase (9.3%), fatigue (8.3%), and diarrhea (7.4%). The results demonstrate extended efficacy and tolerability of lenvatinib plus pembrolizumab in this cohort of patients with previously treated advanced EC. © American Society of Clinical Oncology. |
| Keywords: | clinical trial; endometrial neoplasms; monoclonal antibody; phase 1 clinical trial; endometrium tumor; antibodies, monoclonal, humanized; phenylurea compounds; lenvatinib; carbanilamide derivative; humans; human; female; pembrolizumab |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 5 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-10 |
| Start Page: | 974 |
| End Page: | 979 |
| Language: | English |
| DOI: | 10.1200/jco.22.01021 |
| PUBMED: | 36608305 |
| PROVIDER: | scopus |
| PMCID: | PMC9928628 |
| DOI/URL: | |
| Notes: | Article -- MSK corresponding author is Vicky Makker -- Export Date: 1 March 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
265Makker -
609Aghajanian
Related MSK Work